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For quality control purpose, an approach of combining chromatographic ﬁngerprint of Huaijiao pill (HP)
and simultaneous determination of its major bioactive components was developed using high performance
liquid chromatography coupled with diode array detector (HPLC–DAD). For ﬁngerprint analysis, 16 peaks
were selected as the characteristic peaks to evaluate the similarities of different samples collected from
different batches of three manufacturers. The similarities of 17 Huaijiao pill samples were beyond 0.966,
indicating that samples from different batches and manufacturers were, to some extent, consistent. Ad-
ditionally, simultaneous quantiﬁcation of seven bioactive markers, namely sophoricoside, baicalin, nar-
ingin, genistein, rutin, quercetin and 5-O-methylvisammioside, in HP was performed to interpret the
quality consistency. The validation of the proposed approach was acceptable, with the accuracy of 90.2%–
106.9% in recovery test. The intra-day and inter-day precisions of the method were evaluated and the RSD
values were less than 2.81%. The results from the quantitative data showed that the contents of six marker
compounds (except for 5-O-methylvisammioside) were quite consistent between batches produced by one
manufacturer and signiﬁcantly distinctive among different manufacturers. The proposed approach was
expected to be developed as a powerful tool for the quality control of HP.
& 2016 Xi'an Jiaotong University. Production and hosting by Elsevier B.V. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Huaijiao pill (HP), an ancient traditional Chinese medicine
(TCM) widely used across China, is prepared from six Chinese
medicinal herbs including Sophorae Fructus (Sophora japonica L.),
Sanguisorbae Radix (Sanguisorba ofﬁcinalis L.), Scutellariae Radix
(Scutellaria baicalensis Georgi), Aurantii Fructus (Citrus aurantium
L.), Angelicae Sinensis Radix (Angelica sinensis (Oliv.) Diels) and
Saposhnikoviae Radix (Saposhnikovia divaricata (Turcz.) Schischk).
It is commonly applied in clinical practice for the treatment of
hematochezia, edema and carbuncle caused by haememorrhoids
through clearing heat in bowels and dispelling wind, cooling blood
for hemostasis, eliminating swelling and easing pain [1]. Moreover,
HP is reported to treat hypertension, chronic pharyngitis and acne,
and satisfactory effects were obtained [2–4]. Modern pharmaco-
logical studies have demonstrated its efﬁcacy in inhibiting anti-Lea
agglutinin, stopping bleeding, anti-tumor, anti-inﬂammation, anti-
aging and antiatheroscloresis [5–8]. According to Chinese medi-
cine therapy, Sophorae Fructus is the principal component of HP
[9]. According to modern pharmacological researches, the efﬁcacyon and hosting by Elsevier B.V. Th
University.of Sophorae Fructus is associated with its ﬂavonoides including
sophoricoside, rutin, genistein and quercetin. Sophoricoside, the
main bioactive constituent of Sophorae Fructus, shows inhibitory
effects on chemical mediators involving in inﬂammatory response.
It was identiﬁed as a selective inhibitor of cyclooxygenase (COX)-2
activity [10]. Meanwhile, sophoricoside and genistein (well known
as a phytoestrogen of soy products, and were reported to prevent
cancer and osteoporosis) exhibit inhibitory effects on proin-
ﬂammatory cytokines, IL-5, IL-3, granulocyte-macrophage colony-
stimulating factor (GM-CSF) and IL-6 bioactivities [11]. All these
supplementary herb components provide a therapeutic function
via synergistic effects with the principal drug.
Unlike the synthetic drugs, TCMs exert the curative effects
based on the synergic effects of their multi-components. More
than 100 manufacturers produce HP across China. The composi-
tion of these herbs can vary depending on geographical source,
cultivation conditions, harvest time, storage, and pretreatment.
However, only three bioactive components of it, i.e., sophoricoside,
naringin and baicalin, have been determined through ofﬁcially
conducted quality control of HP presently [1]. Anaphylactic reac-
tion reported is induced by taking HPs [12,13]. Therefore, an in-
tegral quality control approach based on the multiple constituents
of HP is urgently needed to ensure the efﬁcacy and safety of the
drug. Fingerprint has been internationally accepted as an efﬁcient
technique over the last two decades for the authentication andis is an open access article under the CC BY-NC-ND license
Table 1
Statistical results of linear regression equation analysis in the determination of seven bioactive components in HP.
Analyte Regression equation (Y¼ aX+ b) r2 (n ¼ 6) Linear range (μg/mL) LOD (μg/mL) LOQ (μg/mL)
Sophoricoside Y¼53656X+1856 0.9998 5.94–118.9 0.021 0.059
Baicalin Y¼32129X-6974.2 0.9996 5.61–112.2 0.109 0.353
Naringin Y¼15874X+1492.8 1.0000 8.91–178.2 0.303 0.954
Genistein Y¼70623X-6707.8 0.9995 0.59–11.8 0.053 0.145
Rutin Y¼16522X+3036 0.9999 2.32–46.4 0.075 0.216
Quercetin Y¼37178X+1813.1 0.9995 0.54–10.8 0.020 0.065
5-O-methylvisammioside Y¼16522X+3036 1.0000 1.16–23.2 0.005 0.017
For the regression equation, Y ¼ aX +b, Y is the peak area while X is the concentration (μg/mL).
Table 2
Results of intra- and inter-day precisions and repeatability (n¼6).
Analyte Precision Repeatability
Intra-day Inter-day Mean
(μg/mL)
RSD (%)
Mean
(μg/mL)
RSD
(%)
Mean
(μg/mL)
RSD
(%)
Sophoricoside 81.92 1.36 83.04 2.81 70.24 2.41
Baicalin 102.54 0.34 106.67 0.79 91.38 0.95
Naringin 42.63 0.89 43.88 1.98 31.39 2.18
Genistein 5.55 1.11 5.83 1.04 1.58 0.99
Rutin 24.81 1.04 26.46 0.88 30.83 0.79
Quercetin 0.99 1.15 1.01 1.93 0.97 1.32
5-O-methylvisammioside was not detected in sample solutions under the separa-
tion condition described in Section 2.2.
S. Wang et al. / Journal of Pharmaceutical Analysis 6 (2016) 249–255250quality control of TCMs [14,15]. Chromatographic ﬁngerprint
technique can be used to characterize both the marker compounds
and the unknown components in a complex system, a strategy
recommended to assess the quality and consistency of botanical
products by the State Food and Drug Administration of China
(SFDA), the European Medicines Evaluation Agency (EMEA), and
the US Food and Drug Administration (USFDA) [16–18].
However, ﬁngerprint is insufﬁcient to control the overall
quality of TCMs since it cannot quantitate bioactive constituents
which are directly related to the quality of the TCMs [19,20]. Re-
cently, some methods combining chromatographic ﬁngerprint and
quantitative determination have been developed and validated for
quality control of herbal preparations [21,22]. So far, several ap-
proaches have been developed for the determination of the
bioactive constituents of HP, such as high performance liquid
chromatography (HPLC) [23,24]. However, to the best of our
knowledge, quality control approaches, which have been pub-
lished, are mainly focused on constituents in one or two of the six
Chinese medicinal herbs in HP [25–27]. In HP, sophoricoside,
baicalin, naringin, genistein, rutin, quercetin and 5-O-methylvi-
sammioside are generally considered as the bioactive components,
and their determinations are respectively well-documented. We
report, for the ﬁrst time, a combinative method using HPLC for
ﬁngerprint and simultaneous quantitation of seven major bioac-
tive constituents in HP. Meanwhile, the combinative method can
be readily utilized as a comprehensive quality control approach for
the TCM formula as well.2. Experimental
2.1. Materials and chemicals
Seventeen samples of Huaijiao pill from three manufacturerswere collected: S1–S7 (sample 1, S1; the abbr. of other samples
were similar) were from Chongqing TongJunGe Pharmaceutical
Co., Ltd, Taiji Group, Chongqing, China; S8–S15 were from
Chongqing Second TCM Co., Ltd, Taiji Group, Chongqing, China;
S16 and S17 were from Wuhan TaiFu Pharmaceutical Co., Ltd,
Wuhan, China. All the samples were water-honeyed pills. Chemical
standards of sophoricoside, baicalin, genistein, rutin, quercetin and
5-O-methylvisammioside were purchased from the National In-
stitute for the Control of Pharmaceutical and Biological Products
(Beijing, China), and naringin was obtained from Fluka BioChemika
(Switzerland). Acetonitrile and methanol of HPLC grade were
purchased from Dikma Technology Inc.. Ultrapure water was ob-
tained from Southwest Institute of Technical Physics, Chengdu,
China. All other chemicals and reagents were of analytical reagent
grade and used without further puriﬁcation.
2.2. Apparatus and chromatographic conditions
Instrument for analysis was a Shimadzu LC-20A module con-
sisting of an LC-20AB binary pump, a DGU-20A3 degasser, a CTO-
20A thermostatted column compartment and an SPD-M20A UV–
vis diode array detector (Shimadzu, Japan). HPLC ﬁngerprints and
quantitative determinations were performed with LC solution
software (Shimadzu, Japan). The chromatographic separation was
carried out on a Dikma Diamonsil C18 column (250 mm4.6 mm,
5 mm) with a Dikma Diamonsil ODS (10 mm4.0 mm, 5 mm) pre-
column from Dikma Technologies maintained at 35.2 °C. The mo-
bile phases were composed of mobile phase A (acetonitrile-0.05%
phosphoric acid (95:5, v/v) and mobile phase B (acetonitrile-0.05%
phosphoric acid (20:80, v/v) with a gradient program as follows:
0–5 min, linear gradient 0%–10% B; 5–15 min, linear gradient 10%–
20% B; 15–25 min, linear gradient 20%–25% B; 25–30 min, linear
gradient 25%–30% B; 30–36 min, linear gradient 30%–45% B; 36–
47 min, linear gradient 45%–100% B; 47–52 min, isocratic 100% B;
and 52–57 min, linear gradient 100%–0% B at a ﬂow rate of 1.0 mL/
min. The UV absorbance was monitored at 254 nm using DAD. All
injection volumes of sample and standard solutions were 10 μL.
2.3. Preparation of sample and standard solution
1.0 g of HP powder was extracted by ultrasonication for 45 min
with 20 mL of solvent (70% ethanol-glacial acetic acid (80:1, v/v))
in a 50 mL conical ﬂask with cover. The extract was cooled to room
temperature, adjusted the weight back to the pre-extractioin
weight with solvent, and then centrifuged at 10,000 rpm for
10 min. 2 mL of supernatant was transferred to a 10 mL volumetric
ﬂask, and then methanol was added to the scale and shaken
evenly. The solutions were ﬁltered with a 0.45 mmmembrane ﬁlter
prior to HPLC analysis.
Each standard was accurately weighed and dissolved in me-
thanol to produce standard stock solution. A mixed standard stock
solution was then prepared in methanol from the individual
Table 3
Statistical results of recovery of extraction of analytes in HP (n¼9).
Analyte Spiked amount (mg) Recorded amount (mg) RSD (%) Calculated recovery (%) Mean recovery (%)
Sophoricoside 0.144 0.151 0.89 104.9 100.3
0.288 0.279 0.45 96.8
0.432 0.428 0.21 99.1
Baicalin 0.109 0.106 0.32 97.6 100.0
0.218 0.224 0.55 102.5
0.327 0.327 0.04 99.9
Naringin 0.101 0.108 1.35 106.9 100.6
0.202 0.182 0.76 90.2
0.303 0.317 1.04 104.6
Genistein 0.006 0.005 0.67 92.7 96.1
0.011 0.010 0.34 94.4
0.017 0.017 0.58 101.1
Rutin 0.107 0.105 0.25 98.1 101.0
0.214 0.216 0.49 101.0
0.321 0.333 0.81 103.8
Quercetin 2.45×10-3 2.41×10-3 0.34 98.4 96.3
4.90×10-3 4.80×10-3 0.28 98.0
7.35×10-3 6.81×10-3 0.54 92.6
5-O-methylvisammioside 5.2×10-3 5.3×10-3 0.65 101.9 99.1
10.4×10-3 10.2×10-3 0.23 98.1
15.6×10-3 15.2×10-3 0.44 97.4
Table 4
Quantitative determination of seven markers in 17 HP samples.
Sample no. Contents (n¼3, mg/g; mean±SD)
Sophoricoside Baicalin Naringin Genistein Rutin Quercetin
S1 7.42±0.37 9.28±0.25 4.91±0.22 0.53±0.12 2.39±0.14 0.10±0.03
S2 6.95±0.21 9.85±0.15 nd 0.11±0.04 2.68±0.08 trace
S3 7.35±0.17 7.18±0.16 nd 0.15±0.00 2.61±0.05 0.01±0.00
S4 7.03±0.25 9.57±0.43 nd 0.11±0.00 2.86±0.03 trace
S5 6.68±0.13 9.14±0.31 nd 0.15±0.00 2.70±0.01 0.03±0.00
S6 7.36±0.15 9.83±0.23 nd 0.11±0.01 2.89±0.01 trace
S7 7.69±0.19 10.38±0.34 nd 0.13±0.00 3.06±0.04 0.01±0.00
S8 6.38±0.08 3.44±0.08 4.29±0.24 0.19±0.03 3.46±0.05 0.06±0.00
S9 5.89±0.07 4.98±0.03 5.86±0.09 0.18±0.01 3.25±0.01 0.05±0.01
S10 5.51±0.09 6.13±0.15 5.26±0.11 0.22±0.00 1.31±0.00 0.01±0.00
S11 6.56±0.23 4.74±0.01 3.56±0.07 0.17±0.00 3.65±0.09 0.03±0.00
S12 6.33±0.16 4.70±0.03 3.90±0.05 0.19±0.01 3.56±0.06 0.02±0.00
S13 6.15±0.06 4.08±0.01 5.38±0.13 0.18±0.01 3.41±0.04 0.06±0.01
S14 5.80±0.07 4.45±0.01 5.89±0.04 0.19±0.00 3.27±0.01 0.03±0.00
S15 5.97±0.01 4.50±0.00 nd 0.15±0.00 2.10±0.00 0.05±0.01
S16 5.83±0.03 6.90±0.07 nd 0.17±0.00 1.77±0.03 0.04±0.00
S17 4.50±0.05 5.88±0.01 nd 0.15±0.01 1.65±0.07 0.03±0.00
Average 6.44±0.83 6.77±2.42 4.88±0.88 0.18±0.10 2.74±0.70 0.04±0.02
RSD (%) 12.83 35.72 18.05 52.46 25.61 64.87
nd: under detected limit; trace: under quantiﬁcation limit.
5-O-methylvisammioside was not detected in sample solutions under the separation condition described in Section 2.2.
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obtained through diluting the stock solution to a series of con-
centrations in order to construct the calibration curves. All the
standard solutions were stored in a refrigerator at 4 °C and
brought to room temperature before analysis.2.4. Preparation of negative control solution and unilateral sample
solution
According to the proportion and the preparation technology of
the prescription, the negative sample was prepared without So-
phorae Fructus, Scutellariae Radix and Aurantii Fructus. Then, the
negative control solution was prepared in accordance with the
preparation method of the test solution in Section 2.3. Similarly,
six solutions of the unilateral sample were prepared respectively.2.5. Method validation
2.5.1. Speciﬁcity
The speciﬁcity test was performed by analyzing the negative
control solution, and then compared its chromatogram with those
of the mixed standard solution and the sample solution.
2.5.2. Linearity, limit of detection (LOD) and limit of quantiﬁcation
(LOQ)
The linearity study was achieved by diluting stock solution into
a series of concentrations. The calibration curves were constructed
with six concentrations in triplicate. Calibration curves for all the
compounds were generated by plotting the integrated chromato-
graphy peak area (Y) versus the concentrations (X, μg/mL) of the
mixed standard solutions. Results were expressed as the values of
the correlation coefﬁcient (r2). LOD and LOQ were calculated by
diluting the standard solution when signal-to-noise ratios (S/N) of
Fig. 1. HPLC chromatographic ﬁngerprints of (A) 17 HP samples and (B) simulative median chromatogram obtained by Similarity Evaluation System for Chromatographic
Fingerprint of Traditional Chinese Medicine software (2004A). The chromatograms marked with S1–S17 and R represent 17 HP samples and the simulative median chro-
matogram, respectively. The peaks marked with 1–16 in the simulative median chromatogram represent 16 characteristic peaks, and peaks marked with 17 and 18 were
naringin and quercetin, respectively. The separation condition was described in Section 2.2.
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2.5.3. Precision, repeatability and accuracy
Intra- and inter-day precision tests were performed by ana-
lyzing sample solutions (S1) during a single day (n¼6) and on six
different days (n¼3), respectively. For repeatability test, six in-
dependent sample solutions (S1) were prepared by the same
procedure noted in Section 2.3. An accurately known amount of
the corresponding marker compounds at three concentration le-
vels (0.5, 1.0 and 1.5 times of the concentration) was spiked into a
previously analyzed HP sample solution (S1), and three con-
centration levels of solutions were prepared and then analyzed.
Recovery tests were performed by comparatively analyzing spiked
and unspiked samples. Relative standard deviation (RSD) was used
to describe precision, repeatability and recovery.2.6. HPLC ﬁngerprints
2.6.1. Similarity calculation of the HPLC ﬁngerprints
All determinations were carried out in triplicate, and the data
were analyzed by the Similarity Evaluation System for Chroma-
tographic Fingerprint of Traditional Chinese Medicine software
(Version 2004 A) which was developed by the Chinese Pharma-
copoeia Committee. The median method was chosen to ﬁt the
ﬁngerprint chromatograms and the correlation coefﬁcient was
employed to evaluate the similarity.
2.6.2. Assignment of the 16 characteristic peaks of the HPLC
ﬁngerprint
Chromatograms of six unilateral sample solutions were com-
pared with the sample ﬁngerprint chromatogram, respectively.
And the 16 characteristic peaks of the HPLC ﬁngerprint were in-
dividually assigned to the corresponding herbs.3. Results and discussion
3.1. Optimization of HPLC chromatographic conditions
HPLC conditions including mobile phase and detection wave-
length were investigated to optimize chromatographic separation.
The effect of mobile phase composition on chromatographic se-
paration was investigated, using methanol-0.05% phosphoric acid,
acetonitrile-0.2% acetic acid, and acetonitrile-0.05% phosphoric acid,
respectively. Finally, the proposed mobile phase of acetonitrile-0.05%
phosphoric acid (v/v) had the most effective HPLC result.
The wavelength of the target compounds in HP was selected by
a DAD full wavelength scan (190–400 nm). Most chemical con-
stituents in HP had strong UV absorbance at 254 nm. Therefore,
254 nm was chosen for obtaining the HP ﬁngerprints. Meanwhile,
the maximum absorption wavelengths, 260 nm (for ﬂavonoides
including sophoricoside, genistein, rutin and quercetin), 277 nm
(for baicalin), 283 nm (for naringin) and 293 nm (for 5-O-me-
thylvisammioside), were selected for the detection, respectively.
Optimal HPLC condition used in this study is shown as follows. The
mobile phases were composed of mobile phase A (acetonitrile-
0.05% phosphoric acid (95:5, v/v)) and mobile phase B (acetoni-
trile-0.05% phosphoric acid (20:80, v/v)) with a gradient program.
The UV absorbance was monitored at 254 nm using DAD. All in-
jection volumes of sample and standard solutions were 10 μL.
3.2. Optimization of extraction conditions
Optimization of extraction conditions was investigated
through single factor experiment. Sample pretreatment condi-
tions were optimized by investigating the effect of extraction
solvents and methods on the extraction efﬁciency of chemical
markers used for HPLC ﬁngerprinting and quantiﬁcation. 70%
ethanol-glacial acetic acid (80∶1, v/v) was found to be the most
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HPLC results.
Extraction methods including ultrasonication and heat-reﬂux
were then investigated for extraction efﬁciency using 70% ethanol-
glacial acetic acid (80∶1, v/v) as the extraction solvent. The results
showed that the extraction efﬁciencies of the two techniques were
comparable, and ultrasonication was chosen because of its simple
and rapid performance.
Then, the ratio of sample-extraction solvent with 1 g∶10 mL,
1 g∶20 mL, 1 g∶40 mL was studied respectively, and a ratio of
1 g∶20 mL was selected according to the HPLC results, which was
economic and environmental friendly. Extraction time under ul-
trasonication was also tested, and the results showed that all the
marker compounds were extracted within 45 min, and that longer
period of ultrasonication did not increase the contents sig-
niﬁcantly. The optimal extraction conditions for HP used in this
study are detailed as follows. 1.0 g of HP powder was extracted by
ultrasonication for 45 min with 20 mL of solvent (70% ethanol-
glacial acetic acid (80∶1, v/v)) in a 50 mL conical ﬂask with cover.
The extract was cooled to room temperature, adjusted the weight
back to the pre-extractioin weight with solvent, and then cen-
trifuged at 10,000 rpm for 10 min. 2 mL of supernatant was
transferred to a 10 mL volumetric ﬂask, and then methanol was
added to the scale and shaken evenly. The solutions were ﬁltered
with a 0.45 mm membrane ﬁlter prior to HPLC analysis.
3.3. Method validation
3.3.1. Speciﬁcity
No interfering peaks were observed in any chromatograms of
the negative control solution compared with the sample solution
and the mixed standard solution at the same retention time.
3.3.2. Linearity, LOD and LOQ
As shown in Table 1, acceptable results of the regression ana-
lysis, the correlation coefﬁcients (r2), LOD and LOQ were obtained
for all the analytes. The LOD and the LOQ were in the range of
0.005–0.303 μg/mL and 0.017–0.954 μg/mL for all the analytes,
respectively. DAD detections have acceptable linearity beyond
0.9995.
3.3.3. Precision, repeatability and accuracy
For precision test, statistical data showed that the RSD values of
six compounds (except that 5-O-methylvisammioside was not
detected in sample solutions under the optimized method. One
possible explanation was that its content was far too low.) were in
the range of 0.34%–1.36% for intra-day precision and 0.79%–2.81%
for inter-day precision. The RSD values of repeatability were less
than 2.41% (Table 2). For recovery test, mean recoveries of the
seven standard substances were between 96.1% and 101.0%, with
RSD values less than 1.35% (n¼9) (Table 3). These validation re-
sults described above indicated that the developed method is
acceptable.
3.4. Quantitative determination of the seven marker compounds in
HP
In this study, the proposed HPLC–DAD method was successfully
applied to the simultaneous determination of the seven markers in
HP samples. The identity of the marker compound peaks in the
chromatogram was conﬁrmed by their retention time and their
DAD proﬁles. The contents of the marker compounds in 17 sam-
ples from three manufacturers are summarized in Table 4. Sig-
niﬁcant variances among the contents of the same markers were
observed from different samples. For example, the highest content
of baicalin was 10.38 mg/g in sample S7 and the lowest (3.44 mg/
Table 6
The relative peak areas (RPA) of 16 characteristic peaks for 17 HP samples.
Sample no. Peak no.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
S1 0.071 0.152 0.160 0.075 0.226 0.107 0.501 0.100 0.087 0.427 1.000 0.336 0.060 0.083 0.174 0.092
S2 0.047 0.180 0.196 0.070 0.225 0.132 0.131 0.114 0.085 0.483 1.000 0.380 0.107 0.018 0.087 0.056
S3 0.041 0.175 0.193 0.078 0.236 0.128 0.278 0.109 0.099 0.467 1.000 0.272 0.064 0.022 0.180 0.104
S4 0.044 0.174 0.195 0.072 0.226 0.138 0.210 0.117 0.093 0.481 1.000 0.367 0.103 0.018 0.079 0.051
S5 0.053 0.200 0.233 0.090 0.212 0.141 0.608 0.130 0.108 0.508 1.000 0.364 0.099 0.024 0.093 0.064
S6 0.048 0.171 0.192 0.071 0.218 0.137 0.240 0.111 0.089 0.468 1.000 0.363 0.102 0.018 0.077 0.052
S7 0.045 0.194 0.193 0.073 0.223 0.137 0.237 0.114 0.092 0.475 1.000 0.363 0.102 0.019 0.077 0.049
S8 0.064 0.156 0.167 0.095 0.298 0.181 0.492 0.116 0.140 0.463 1.000 0.150 0.029 0.035 0.263 0.147
S9 0.074 0.162 0.173 0.095 0.292 0.181 0.545 0.122 0.130 0.469 1.000 0.226 0.049 0.034 0.253 0.155
S10 0.042 0.216 0.234 0.052 0.138 0.050 0.534 0.137 0.067 0.455 1.000 0.285 0.072 0.047 0.169 0.108
S11 0.053 0.150 0.165 0.094 0.301 0.187 0.398 0.116 0.132 0.462 1.000 0.197 0.041 0.034 0.269 0.140
S12 0.053 0.158 0.170 0.095 0.304 0.189 0.387 0.114 0.130 0.465 1.000 0.201 0.042 0.035 0.276 0.149
S13 0.068 0.160 0.172 0.094 0.309 0.182 0.456 0.120 0.129 0.472 1.000 0.177 0.036 0.035 0.277 0.151
S14 0.059 0.159 0.171 0.093 0.305 0.186 0.383 0.120 0.127 0.474 1.000 0.204 0.042 0.037 0.269 0.156
S15 0.075 0.202 0.218 0.090 0.208 0.119 0.629 0.121 0.105 0.483 1.000 0.219 0.048 0.028 0.233 0.138
S16 0.037 0.208 0.213 0.082 0.211 0.063 0.204 0.129 0.085 0.524 1.000 0.323 0.086 0.036 0.193 0.102
S17 0.076 0.207 0.261 0.111 0.242 0.116 0.323 0.122 0.103 0.609 1.000 0.365 0.087 0.039 0.188 0.094
Average 0.056 0.178 0.195 0.084 0.245 0.140 0.386 0.118 0.106 0.481 1.000 0.282 0.069 0.033 0.186 0.106
S.D. 0.013 0.022 0.029 0.014 0.048 0.042 0.153 0.008 0.022 0.039 0.000 0.080 0.028 0.016 0.078 0.041
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order of baicalin4 sophoricoside4 rutin4 genistein4quercetin,
determined in samples S1, S2, S3, S4, S5, S6, S7 (S1–S7 were ob-
tained from one manufacturer), S16 and S17 (these two samples
were from the same manufacturer). However, the order
(sophoricoside4baicalin4naringin4rutin4genistein4querce-
tin) was different in samples S8, S9, S11, S12, S13 and S14 which
were produced by the same manufacturer. Moreover, naringin was
only detected in samples S1, S8, S9, S10, S11, S12, S13 and S14.
These data suggested that the batch-to-batch consistency of HP
was good under the same manufacturing conditions, which were
consistent with results from the chromatographic ﬁngerprints.
However, the content of each marker determined between man-
ufacturers, was signiﬁcantly different with RSD values of 12.83%–
64.87%, indicating the large variations in their quality. A possible
explanation of the result is that the herbal materials and manu-
facturing processes applied by manufacturers are quite different. It
is noteworthy that chromatographic ﬁngerprints may not fully
monitor the quality consistency. Therefore, more attention should
be paid to quality consistency of HP to ensure its clinical efﬁcacy.
Our results accorded with the previous studies. Compared to
chromatographic ﬁngerprint alone, chromatographic ﬁngerprint
combined with quantitative techniques for determining marker
compounds is a better tool for quality consistency evaluation of
herbal preparations [22,28,29].
3.5. HPLC ﬁngerprints
3.5.1. Evaluation of the HPLC ﬁngerprints
Chromatographic ﬁngerprints were generated for 17 HP sam-
ples from three manufacturers, and 16 peaks were found in each
individual sample (Fig. 1A). A simulative median ﬁngerprint was
generated by the professional software by analyzing all the 17
samples (Fig. 1B). The simulative median chromatogram of HP had
16 well-resolved “characteristic peaks”. Sophoricoside (peak 11)
was an important bioactive component of HP with a consistently
high content and a suitable retention time, so peak 11 was chosen
as the reference peak to calculate the relative retention time (RRT)
and relative peak area (RPA). RRT and RPA of the 16 characteristic
peaks in 17 samples are shown in Table 5 and Table 6.
Chromatographic proﬁles were generally consistent although
the absorption intensity of some peaks and the number of peakswere slightly different for some samples. The similarity of each
chromatograph against simulative median chromatogram was
calculated: the similarities of S1–S17 were 0.989, 0.975, 0.998,
0.985, 0.979, 0.987, 0.966, 0.987, 0.986, 0.981, 0.993, 0.993, 0.990,
0.993, 0.979, 0.988, and 0.990. All the similarity values were in the
range of 0.966–0.998, indicating that similar chemical components
were present in these samples regardless of manufacturer.
3.5.2. Assignment of the 16 characteristic peaks of the HPLC
ﬁngerprint
To determine which herb each compound originated from, a
comparative study was conducted using the individual extracts of
six herbs. In the light of comparisons, the results of this study are
as follows: Peaks marked with 1 and 7 were from Sanguisorbae
Radix; peaks marked with 2, 3, 4, 5, 6, 8, 9 10, 11 and 14 were from
Sophorae Fructus; and peaks marked with 12, 13, 15 and 16 were
from Scutellariae Radix. Moreover, naringin was from Aurantii
Fructus and quercetin was from Sophorae Fructus.4. Conclusions
The proposed HPLC ﬁngerprint method combined with quan-
titative analysis is an efﬁcient and comprehensive tool for quality
consistency evaluations of HP. HPLC ﬁngerprint of the chromato-
graphic proﬁles could serve as the preferred tool for quality con-
sistency of HP by similarity comparison. Furthermore, simulta-
neous quantiﬁcation of seven marker compounds from each in-
dividual herbal present in HP can be carried out in a single HPLC
chromatogram, and used as a supplemental tool for quality con-
sistency evaluation. To the best of our knowledge, this is the ﬁrst
report for both the ﬁngerprint of HP and simultaneous determi-
nation of its seven major bioactive components. Overall, this study
sets a good example for quality consistency evaluation using a
combination of HPLC ﬁngerprint and quantitative analysis.References
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